Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders
The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.
Riggs, P., et al. (2011). Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. Journal of the American Academy of Child & Adolescent Psychiatry 50(9):903-14.
- Addiction Research and Treatment Services (ARTS), Colorado
- Western Psychiatric Institute and Clinic (WPIC), Pennsylvania
- Rehab After Work - Life Counseling Services, Pennsylvania
- Gateway Health Systems, Florida
- Operation PAR, Inc., Florida
- St. Luke's Roosevelt Hospital Center, New York
- Mountain Manor Treatment Programs, Maryland
- SSTAR of Rhode Island, Rhode Island
- SSTAR of Massachusetts (Stanley Street Treatment & Resources, Inc.), Massachusetts
- Lexington/Richland Alcohol and Drug Abuse Council, South Carolina
- Mental Health and Mental Retardation of Tarrant County, Texas
Get this Publication
Formed with SAMHSA to reduce the gap between research results and treatment.